Venetoclax

2:07
Significance of MRD in CLL
Tanya Siddiqi
4:26
TRANSCEND-CLL-004: lisocabtagene maraleucel in CLL
Tanya Siddiqi
3:38
Impact of increased drug availability on acute leukemia
Oliver Ottmann
2:03
ESH AL highlights: management of T-cell malignancies
John DiPersio
9:55
Immune checkpoint inhibitors in acute leukemia
Naval Daver
5:01
Treatment options for high-risk AML
Nigel Russell
5:31
The role of venetoclax in older patients with AML
Andrew Wei
2:14
Update on the AML treatment landscape
Thorsten Braun
4:43
Treatment of NPM1-mutated AML: intensive standard treatment
Christoph Röllig
4:17
AML: genetic screening and subtypes
Naval Daver
5:14
EHA 2020 CLL highlights: CLL14 & CAPTIVATE
Paolo Ghia
1:57
Venetoclax and azacitidine for AML ineligible for standard induction
Raúl Córdoba
2:46
Challenges in the use of BTK inhibitors for CLL
Florence Cymbalista
4:13
Front-line and R/R updates in CLL from EHA
Peter Hillmen
5:54
Updates from CAPTIVATE: ibrutinib and venetoclax for CLL
Tanya Siddiqi
2:46
Combining B-cell receptor antagonists and venetoclax in CLL
Richard Furman
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals